Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H ( (HK:1541) ) has issued an announcement.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has called its annual general meeting for May 28, 2026, in Shanghai, where shareholders will review 2025 operational and financial performance. They will consider reports from the board and supervisory committee, the 2025 annual and final financial reports, the 2026 budget, the 2025 profit distribution plan, and remuneration packages for directors and supervisors for 2026.
Shareholders will also vote on reappointing Deloitte Touche Tohmatsu as the company’s auditor for 2026 and on granting the board a broad mandate to issue new shares and dispose of treasury shares. The proposed mandate would give directors flexibility over share class, pricing, timing, allocation to existing shareholders, and use of proceeds, potentially affecting future capital-raising and shareholder dilution dynamics.
More about ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a PRC-incorporated biopharmaceutical company listed in Hong Kong. It focuses on developing and commercializing innovative immuno-oncology therapies, targeting cancer treatment markets in China and internationally.
Average Trading Volume: 1,679,550
Technical Sentiment Signal: Sell
Current Market Cap: HK$3.94B
Learn more about 1541 stock on TipRanks’ Stock Analysis page.